Table 1.
Demographic and clinical information.
| Immunocompromised (N=56) | Non-Immunocompromised (N=184) | Total (N=240) | P value | |
|---|---|---|---|---|
|
| ||||
| Sex, n (%) | 0.2 | |||
| Female | 32 (57.1%) | 126 (68.5%) | 158 (65.8%) | |
| Male | 24 (42.9%) | 58 (31.5%) | 82 (34.2%) | |
|
| ||||
| Age, Median (Q1, Q3) | 55 (45, 67) | 46 (33, 59) | 49 (34–60) | 0.001 |
|
| ||||
| Race, n (%) | 0.8 | |||
| Asian | 1 (1.8) | 10 (5.4) | 11 (4.6) | |
| Black or AA | 5(8.9) | 19 (10.3) | 24 (10.0) | |
| Other/Unknown | 5(8.9) | 16 (8.7) | 21 (8.8) | |
| White | 45 (80.4) | 139 (75.5) | 184 (76.7) | |
|
| ||||
| Ethnicity | 0.5 | |||
| Hispanic or Latino | 5(8.9) | 17 (9.2) | 22 (9.2) | |
| Not Hispanic or Latino | 47 (83.9) | 143 (77.7) | 190 (79.2) | |
| Other/Unknown | 4 (7.1) | 24 (13.0) | 28 (11.7) | |
|
| ||||
| Inpatient, n (%) | 7 (12.5) | 8(4.3) | 15 (6.2) | 0.051 |
|
| ||||
| Number of vaccinations, median number, (Q1, Q3) | 3(3–4) | 3 (2–3) | 3(2–4) | <0.001 |
|
| ||||
| mAb use, n (%) | 24* (42.9) | 10 (5.4) | 34 (14.2) | <0.001 |
|
| ||||
| Antiviral use, n (%) | 40 (71.4) | 57 (31.0) | 97 (40.4) | <0.001 |
|
| ||||
| Immunocompromise group, n (%) | <0.001 | |||
| S-HT | 12 (21.4) | 0 (0.0) | 12 (5.0) | |
| S-A | 13 (23.2) | 0 (0.0) | 13 (5.4) | |
| NS | 31 (55.4) | 0 (0.0) | 31 (12.9) | |
| None | 0(0.0) | 184 (100.0) | 184 (76.7) | |
|
| ||||
| Symptom duration, median days** (Q1, Q3) | 5 (4, 7) | 4 (3, 6) | 4 (3, 6) | 0.04 |
|
| ||||
| Variant*** | <0.001 | |||
| Delta | 3 (5.4) | 43 (23.4) | 46 (19.2) | |
| Omicron | 48 (85.7) | 137 (74.5) | 185 (77.1) | |
| Other/Unknown | 5(8.9) | 4 (2.2) | 9(3.8) | |
Q1 and Q3, quartile 1 and quartile 3; AA, African American; mAb, monoclonal antibody; S-HT, severe with malignant hematology or transplant history; S-A, severe autoimmune/B-cell deficient; NS, non-severe immunocompromising condition.
*,
four participants received Mab after blood draws.
**,
Symptom duration indicates the duration between symptom onset (patient report or first positive test if asymptomatic screening) and first nasal swab collected by the study group.
***,
Variant information was obtained by either Spike or whole genome sequencing or by epidemiological information (time period when the participant was infected).